OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors

On October 19, 2026 OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, reported that the China National Medical Products Administration (NMPA) has accepted two new Investigational New Drug (IND) applications (CXSL2601129 and CXSL2601130) to evaluate cesalatamig (AI-081), the company’s differentiated PD-1/VEGF bispecific antibody, in novel combination regimens for patients with advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The INDs will support clinical studies evaluating cesalatamig in combination with antibody-drug conjugates (ADCs) across selected solid tumors and with pan-RAS inhibitors in molecularly defined patient populations.

The studies represent an important expansion of OncoC4’s strategy to establish cesalatamig as a foundational immuno-oncology backbone with the potential to enhance activity across multiple therapeutic modalities.

"The acceptance of these new IND applications in China marks an important milestone in the evolution of our cesalatamig development strategy," said Dr. Pan Zheng, Co-founder and Chief Medical Officer of OncoC4. "We believe the dual targeting of PD-1 and VEGF may provide a highly complementary platform for combination approaches. By integrating cesalatamig with next-generation ADCs and precision oncology therapies such as RAS pathway inhibitors, we aim to unlock new treatment options for patients whose cancers remain difficult to treat with current standards of care."

Cesalatamig is designed to simultaneously inhibit tumor angiogenesis and enhance anti-tumor immune responses through dual blockade of VEGF and PD-1. OncoC4 is evaluating cesalatamig across multiple tumor types in ongoing clinical studies in the United States and China. In September 2026, cesalatamig received U.S. FDA Fast Track Designation for non-small cell lung cancer (NSCLC) that progressed after concurrent or sequential PD-(L)1-targeted immunotherapy and platinum-based chemotherapy.

The ADC combination program is intended to evaluate the potential for cesalatamig to enhance anti-tumor activity through complementary mechanisms of action, leveraging the targeted cytotoxic activity of ADCs together with immune activation and vascular normalization associated with dual PD-1/VEGF blockade.

The precision medicine program will evaluate cesalatamig in combination with inhibitors of the RAS signaling pathway, one of the most frequently dysregulated oncogenic pathways across solid tumors1-2. These studies will assess whether concurrently targeting tumor-intrinsic signaling and the tumor microenvironment can produce deeper and more durable clinical responses in biomarker-selected patient populations.

"Having obtained clinical proof-of-concept data demonstrating the activity of cesalatamig monotherapy in several challenging cancer indications, as well as its combinability with chemotherapy, we are now advancing rational combinations with precision therapies," said Dr. Yang Liu, Co-founder, Chief Executive Officer and Chief Scientific Officer of OncoC4. "These INDs expand our ability to evaluate cesalatamig in high-priority combinations and advance our vision of precision immuno-oncology."

Patient enrollment is expected to begin following NMPA approval and completion of site activation activities.

About Cesalatamig

Cesalatamig (AI-081) is a differentiated PD-1/VEGF bispecific antibody designed to promote stronger cooperative interaction between PD-1 and VEGF blockade through high affinity to PD-1 and substantially higher VEGF-binding affinity than bevacizumab-based PD-(L)1/VEGF bispecific antibodies. As a result, cesalatamig shows best-in-class potential that favors its action in a PD-1 and VEGF-rich tumor microenvironment. Cesalatamig also has more effective Fc-silencing modifications to avoid the depletion of PD-1-positive effector T cells. The U.S. FDA granted cesalatamig Fast Track Designation for the treatment of non-small cell lung cancer (NSCLC) that progressed after concurrent or sequential PD-(L)1-targeted immunotherapy and platinum-based chemotherapy in September 2026.

(Press release, OncoC4, OCT 19, 2026, View Source [SID1234673585])

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

On October 19, 2026 Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit Therapeutics Inc. reported an international multicenter Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Built on Akeso’s first-in-class immuno-oncology (IO) cornerstone therapy ivonescimab (PD-1/VEGF bispecific antibody), the study will assess the efficacy and safety of multiple treatment regimens, including the combination of ivonescimab with Akeso’s first-in-class bispecific antibody cadonilimab (PD-1/CTLA-4 bispecific antibody), in previously untreated patients with advanced clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. Participants will be randomized to receive ivonescimab in combination with cadonilimab, ivonescimab in combination with ipilimumab, ivonescimab monotherapy, or the established international standard-of-care comparator regimen of nivolumab plus ipilimumab.

Cadonilimab is the world’s first approved immuno-oncology bispecific antibody and the only PD-1/CTLA-4 bispecific antibody to have received regulatory approval. It is currently approved for three indications: first-line gastric cancer, first-line cervical cancer, and recurrent or metastatic cervical cancer.

Cadonilimab is being evaluated in 13 Phase III/registrational clinical studies, including two international multicenter trials. In addition, dozens of Phase I/II studies have been conducted across more than 30 tumor types, including renal cell carcinoma, demonstrating robust anti-tumor activity and a favorable safety profile.

Currently, regimens combining a PD-1 inhibitor with a CTLA-4 inhibitor, such as nivolumab plus ipilimumab, and those combining a PD-1 inhibitor with a tyrosine kinase inhibitor (TKI), such as pembrolizumab plus axitinib, represent established first-line standards of care for advanced renal cell carcinoma internationally. Building on ivonescimab as a cornerstone therapy, combinations with the next-generation IO agent cadonilimab, a PD-1/CTLA-4 bispecific antibody, and additional agents will allow further exploration of the synergistic, complementary and differentiated effects across distinct targets and mechanisms of action. This approach has the potential to further improve clinical benefit and offer patients with advanced renal cell carcinoma more diverse and precise novel treatment options.

Early clinical studies have shown that both cadonilimab and ivonescimab demonstrate promising antitumor activity with manageable safety profiles in renal cell carcinoma, providing a strong rationale for further evaluation of their combination in advanced disease.

Earlier this year, Summit announced a clinical trial collaboration to evaluate the safety and efficacy of ivonescimab in combination with casdatifan, a HIF2α inhibitor from Arcus Biosciences, in ccRCC, including first-line metastatic disease.

(Press release, Akeso Biopharma, OCT 19, 2026, View Source [SID1234673584])

SystImmune, Inc. to Present New Phase 3 Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated NSCLC, HR+ Breast Cancer, and Phase 2 Data in Head and Neck Cancer at ESMO 2026

On October 19, 2026 SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, reported that four abstracts for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC), will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 taking place October 23-27 in Madrid, Spain. Iza-bren is being developed under a license and collaboration agreement by and between SystImmune and Bristol Myers Squibb.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data being presented at ESMO (Free ESMO Whitepaper) highlights the continued clinical development of iza-bren across multiple tumor types and treatment settings including:

Late-breaking data from a randomized Phase III study evaluating iza-bren versus platinum-based chemotherapy in Chinese patients with EGFR-mutant non-squamous NSCLC after progression on a third-generation EGFR TKI, addressing the limited treatment options available to this previously treated population
Late-breaking data from a randomized Phase III study evaluating iza-bren versus physician’s choice chemotherapy in Chinese patients with previously treated unresectable locally advanced or metastatic HR+/HER2- breast cancer, who have developed resistance to prior endocrine therapy and CDK4/6 inhibitors
Results from a Phase II study of iza-bren in combination with pembrolizumab in Chinese patients with treatment-naive recurrent or metastatic head and neck squamous cell carcinoma, exploring the potential of combining a first-in-class bispecific ADC with immunotherapy
Results from a Phase II study of iza-bren in combination with osimertinib in Chinese patients with EGFR-mutant locally advanced or metastatic NSCLC in the first line setting, investigating dual-targeted combination strategies in this patient population
"The data presented at ESMO (Free ESMO Whitepaper) 2026 demonstrates the expanding clinical profile of iza-bren across multiple tumor types and treatment paradigms," said Jonathan Cheng, M.D., Chief Medical Officer of SystImmune. "We are pleased to share these presentations, which represent important milestones in our ongoing global development program. The breadth of data being presented, from our two registrational studies to our exploration of iza-bren in combination regimens, underscores our commitment to understanding the full therapeutic potential of iza-bren for patients with difficult-to-treat cancers."

Details of the presentations at ESMO (Free ESMO Whitepaper) are below:
‍‍PANKU-Breast01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic HR+/HER2- Breast Cancer (BC)
Trial Reference: BL-B01D1-306 (NCT06343948), China
Session Title: Proffered paper session: Breast cancer, early and advanced stage
Presentation Number: LBA50
Speaker: Bo Lan (Beijing, China)
Session Date & Time: Friday, October 23rd, 2026, 13:30-15:00 CEST

PANKU-Lung01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in EGFR-Mutant Non-squamous Non‑Small Cell Lung Cancer (NSCLC) After Progression on a Third Generation EGFR TKI
Trial Reference: BL-B01D1-301 (NCT06382116), China
Session Title: Proffered paper session: NSCLC, metastatic
Presentation Number: LBA71
Speaker: Li Zhang (Guangzhou, China)
Session Date & Time: Monday, October 26th, 2026, 08:30-10:00 CET

Phase II Study of Izalontamab Brengitecan (iza-bren) Plus Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Trial Reference: BL-B01D1-204-02 (NCT06437522), China
Session Title: Rapid Oral: Head and Neck Cancer
Presentation Number: 1542RO
Speaker: Dongmei Ji (Shanghai, China)
Session Date & Time: Sunday, October 25, 2026, 14:45-16:15 CET

Phase II Study of Izalontamab Brengitecan (iza-bren) plus Osimertinib in Patients with EGFR Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Trial Reference: BL-B01D1-203 (NCT05880706), China
Session Title: Poster Session: NSCLC Locally Advanced
Presentation Number: 2575P
Speaker: Fei Zhou (Shanghai, China)
Session Date & Time: Monday, October 26, 2026, 12:00-12:45 CET

About izalontamab brengitecan (iza-bren)

Izalontamab brengitecan (iza-bren, BL-B01D1) is a bispecific antibody-drug conjugate (ADC) that targets both EGFR and/or HER3, antigens that are highly expressed in various epithelial cancers and are known to be associated with cancer cell proliferation and survival. Upon target binding and internalization, iza-bren’s therapeutic novel Topo1i payload is released, causing cytotoxic stress that leads to cancer cell death. Iza-bren’s dual mechanism of action also blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. Iza-bren is being developed under a license and collaboration agreement by and between SystImmune and Bristol Myers Squibb.

(Press release, SystImmune, OCT 19, 2026, View Source [SID1234673583])

TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026

On October 19, 2026 TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, reported that a poster featuring TTX-MC138, the Company’s lead therapeutic candidate, has been accepted and will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 in Madrid, Spain, on October 23, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, titled "Phase 1a Clinical Trial of TTX-MC138, a First-in-Class AntagomiR against Advanced Solid Tumors," will highlight the most recent clinical update from the Phase 1a evaluation of TTX-MC138 in patients with advanced solid tumors. TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression.

"We are honored to have the opportunity to present our most recent TTX-MC138 clinical results at ESMO (Free ESMO Whitepaper), one of the world’s leading oncology meetings," said Zdravka Medarova PhD, Chief Scientific Officer of TransCode. "This poster provides an opportunity to share our clinical experience with TTX-MC138 with the global oncology community and highlight our continued development of this novel therapeutic approach."

Presentation Details

Title: Phase 1a Clinical Trial of TTX-MC138, a First-in-Class AntagomiR against Advanced Solid Tumors
Category: Developmental Therapeutics
Poster: Poster 1025P
Date: October 23, 2026
Location: ESMO (Free ESMO Whitepaper) Congress 2026, Madrid, Spain

The ESMO (Free ESMO Whitepaper) Congress 2026 is being held in Madrid, Spain, from October 23 through October 27, 2026.

(Press release, TransCode Therapeutics, OCT 19, 2026, View Source [SID1234673582])

Kansai Medical University Hospital Administers First Patient Dose of DS1025 in Global Phase 1 Clinical Trial Sponsored by Daiichi Sankyo

On October 19, 2026 Department of New Experimental Therapeutics and Early Phase 1 Drug Development Service at Kansai Medical University Hospital, led by Professor Toshio Shimizu, reported the first worldwide dose of DS1025 to a patient in Japan as part of a global, multicenter Phase 1 clinical trial sponsored by Daiichi Sankyo. The global first-patient-first-dose milestone makes Kansai Medical University Hospital the first clinical trial site to administer this specifically engineered, investigational, potential first-in-class CD25 directed antibody drug conjugate (ADC) to a patient.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DS1025 is an investigational, potential first-in-class CD25 directed ADC that builds on the DXd ADC Technology of Daiichi Sankyo by delivering an immune-oncology optimized cytotoxic payload that works to deplete immunosuppressive T-cells (Treg cells) in the tumor microenvironment and activate the immune system to detect and destroy cancer cells. Treg cells can accumulate within tumors and suppress antitumor immune responses. Because CD25 is highly expressed on Treg cells, including those found in tumor tissue, CD25 is being investigated as a target in cancer immunotherapy.

The multicenter, open-label, first-in-human, dose escalation phase 1 trial will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of DS1025 in patients with advanced or metastatic solid tumors with disease progression on or after at least one prior line of standard therapy.

The trial will evaluate primary endpoints of safety and tolerability, including dose-limiting toxicities and adverse events. Secondary endpoints include pharmacokinetics and immunogenicity. Exploratory endpoints include overall response rate, duration of response, and time to response.

The trial is expected to enroll up to 45 adults with advanced, metastatic, or unresectable solid tumors whose disease has progressed following at least one prior line of standard therapy and for whom no further standard treatment is considered suitable. Clinical sites are planned in Asia, including Japan, and Europe.

For Kansai Medical University Hospital, this milestone also reflects its growing role in early-stage international cancer drug development. Through its collaboration with Daiichi Sankyo and other domestic and international partners, Kansai Medical University will continue to contribute to early-stage clinical research and the development of new approaches to cancer treatment.

(Press release, Daiichi Sankyo, OCT 19, 2026, https://www.prnewswire.com/news-releases/kansai-medical-university-hospital-administers-first-patient-dose-of-ds1025-in-global-phase-1-clinical-trial-sponsored-by-daiichi-sankyo-302911249.html [SID1234673581])